Slide 1: Year-to-date and Q3 2022 Results
Year-to-date and Q3 2022 Results Conference call and webcast for investors and analysts 10 November 2022
Slide 2: Forward-looking statements
Forward-looking statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements wit
Slide 3: YTD/Q3 2022 Results: conference call agenda
YTD/Q3 2022 Results: conference call agenda CEO Opening Remarks Pascal Soriot Chief Executive Officer Financial Results Aradhana Sarin Chief Financial Officer Dave Fredrickson EVP, Oncology Business Oncology Susan Galbraith EVP, Oncology R&D Ruud Dobber EVP, BioPharmaceuticals Business BioPharmaceut
Slide 4: CEO Opening Remarks
CEO Opening Remarks Pascal Soriot Chief Executive Officer
Slide 5: YTD and Q3 2022 Results: key updates
YTD and Q3 2022 Results: key updates Robust, broad-based performance supports FY 2022 Core EPS guidance upgrade Total Revenue Core EPS Broad-based performance YTD across our diverse disease areas $5.28 +37% $33.1bn +52% Total Revenue (growth rates at CER): CER CER Oncology $11.5bn, +24% BioPharmaceu
Slide 6: Science-led innovation
Science-led innovation Continued strong pipeline progress since H1 2022 Phase III data readouts danicopan (ALXN2040) ALPHA PNH with clinically significant EVH capivasertib CAPItello-291 HR-positive advanced breast cancer 19 regulatory approvals in major markets, including: Ultomiris (EU, JP) general
Slide 7: AstraZeneca: business fundamentals
AstraZeneca: business fundamentals Growth outlook supported by pipeline delivery, commercial execution and breadth Broad-based portfolio Diverse geographic footprint Broad Proven geographic footprint ability to execute Q3 2022 | % Total Revenue by disease area Q3 2022 | % Total Revenue by geography
Slide 8: Financial Results
Financial Results Aradhana Sarin Chief Financial Officer
Slide 9: Reported Profit and Loss
Reported Profit and Loss Continued strong top-line growth YTD 2022 CER change % total Q3 2022 CER change % total $m % revenue $m % revenue Total Revenue 33,144 37 100 10,982 19 100 - Product Sales 32,200 35 97 10,590 16 96 - Collaboration Revenue 944 >2x 3 392 >3x 4 Gross margin 70.5% +2 pp 71.8% +1
Slide 10: Core Profit and Loss
Core Profit and Loss Continued operating leverage YTD 2022 CER change % total Q3 2022 CER change % total $m % revenue $m % revenue Total Revenue 33,144 37 100 10,982 19 100 - Product Sales 32,200 35 97 10,590 16 96 - Collaboration Revenue 944 >2x 3 392 >3x 4 Gross margin 81.0% +6 pp 80.8% +7 pp Tota
Slide 11: Net debt and cash flow
Net debt and cash flow Continued improvement in cash flow from operations Net Debt Capital allocation priorities $bn Strong investment grade credit rating Reinvestment in the business Value-enhancing business development Progressive dividend policy3 Net debt CFO Capex Deal payments Dividend Other Ne
Slide 12: FY 2022 Guidance (CER)
FY 2022 Guidance (CER) Increasing Core EPS guidance, anticipate FX headwinds to continue February 2022 July 2022 November 2022 FX impact on Total Revenue 0% Total Revenue -1% upgraded -2% Low twenties % Low twenties % -3% High teens % increase increase increase -4% -4% -5% Core EPS -6% upgraded -6%
Slide 13: Strategic R&D and Commercial investment
Strategic R&D and Commercial investment Enables delivery of sustained long-term growth R&D investment Commercial investment Medical Affairs and other New market and indication launches Late-stage investments include camizestrant, eplontersen, Dato-DXd, LCM e.g., Imfinzi, Farxiga, Saphnelo, Ultomiris
Slide 14: Driving operational efficiencies
Driving operational efficiencies Strategic investments and leveraging synergies to improve where and how we work Geographic footprint Alexion integration Digital improvements Align manufacturing network Transitioned to shared Upgrading IT capabilities to evolving product mix market model to support
Slide 15: Oncology
Oncology Dave Fredrickson Oncology Business Susan Galbraith Oncology R&D
Slide 16: Oncology: YTD 2022
Oncology: YTD 2022 Total Revenue $11.5bn, +24% at CER, increasing Product Sales, Collaboration Revenue Q3 2022: key dynamics 4,500 4,000 • Tagrisso, Imfinzi and Lynparza strong double-digit Product 3,500 Sales growth 3,000 • Calquence 63% growth, Enhertu revenues >3x vs. Q3 2021 Total Revenue ($m) 2
Slide 17: Oncology: Q3 2022
Oncology: Q3 2022 Strong global launch performance Imfinzi Calquence Enhertu TOPAZ-1 ELEVATE-TN/ASCEND DESTINY-Breast04 • First-and-only immunotherapy + • US NBRx share in CLL1 >55% • HER2-low mBC post ET and chemo chemotherapy in BTC • US tablet approval • US approval two weeks after • NCCN categor
Slide 18: Oncology: R&D highlights
Oncology: R&D highlights Transformative data in patients with unmet need at ESMO 2022 Tagrisso Lynparza volrustomig adjuvant EGFRm NSCLC (ADAURA) 1st-line maintenance HRD+ OC (PAOLA-1) NSCLC (Phase Ib/II) Best change from baseline (%) • Nearly 3 in 4 patients disease-free at • 5 year OS Lynparza + b
Slide 19: Oncology: R&D highlights
Oncology: R&D highlights New prospects for patients with advanced breast cancer camizestrant capivasertib 2nd-line ER-positive BC (SERENA-2) HR-positive BC (CAPItello-291) • Positive Phase II for oral next-generation • Potential first-in-class AKT inhibitor SERD • Phase III - statistically significa
Slide 20: Advancing our commitment to lung cancer patients with new trials
Advancing our commitment to lung cancer patients with new trials Dato-DXd celarasertib TROP2 ATR Addresses IO resistance TROPION-Lung07 1st-line | non-squamous | adv/met NSCLC | PD-L1 <50% | without AGAs Advanced/metastatic NSCLC LATIFY: with Imfinzi; versus docetaxel Arm A: Dato-DXd 6mg/kg + pembro
Slide 21: BioPharmaceuticals
BioPharmaceuticals Ruud Dobber BioPharmaceuticals Business Mene Pangalos BioPharmaceuticals R&D
Slide 22: BioPharmaceuticals: YTD 2022
BioPharmaceuticals: YTD 2022 Total Revenue $15.1bn, +21% at CER, Farxiga strength, R&I launch momentum CVRM R&I V&I YTD $6.9bn, +19% at CER YTD $4.5bn, +4% at CER YTD $3.7bn, +56% at CER 1,600 1,800 2,500 1,400 1,600 1,400 2,000 Total Revenue ($m) 1,200 Total Revenue ($m) Total Revenue ($m) 1,200 1,
Slide 23: BioPharmaceuticals: R&D highlights
BioPharmaceuticals: R&D highlights e Showcasing strength at ESC and ISA Farxiga eplontersen HFpEF (DELIVER) ATTRv-PN (NEURO-TTRansform) CV death or worsening HF (full population) External placebo Week 35 reduction LSM = -14.8% eplontersen Week 35 reduction LSM = -81.2% • 18% reduction in CV death in
Slide 24: BioPharmaceuticals: R&D highlights
BioPharmaceuticals: R&D highlights e Leadership and breadth across biologics Beyfortus Tezspire LAAB TSLP • EU approval - first single dose preventative option for RSV in broad Phase III severe asthma trials: infant population • Based on MELODY/MEDLEY clinical NAVIGATOR programme • Sustained exacerb
Slide 25: Rare Disease
Rare Disease Marc Dunoyer Chief Executive Officer, Alexion
Slide 26: Rare Disease: YTD 2022
Rare Disease: YTD 2022 Ultomiris gMG launch gains traction, accelerated conversion and global adoption Rare Disease Q3 2022: key dynamics YTD Total Revenue $5.2bn, +10% pro forma1 at CER 2,000 • C5 Franchise growth, +8%1 1,800 ‒ Soliris (6%)1 decline reflecting successful conversion to 1,600 Ultomir
Slide 27: Alexion, AstraZeneca Rare Disease
Alexion, AstraZeneca Rare Disease Continued leadership in Rare Disease, delivering pioneering science Sustained leadership in Complement Expanding beyond Complement Building bridges with multiple novel platforms in bone disorders, metabolics and cardiomyopathy to strengthen collaboration with AstraZ
Slide 28: Rare Disease: R&D highlights
Rare Disease: R&D highlights Proposed LogicBio acquisition enhances genomic capabilities Alexion genomic medicines LogicBio leveraging existing AstraZeneca technologies novel technology platforms Gene therapy Antisense oligonucleotides CRISPR gene editing proprietary gene AAV capsid novel AAV editin
Slide 29: CEO Closing Remarks
CEO Closing Remarks Pascal Soriot Chief Executive Officer
Slide 30: AstraZeneca
AstraZeneca Innovation-led, delivering industry-leading growth through 2025 and beyond Robust life-cycle management Pipeline acceleration in 2023 18 Phase III readouts anticipated, including: Strategic pillars support Innovative late-stage pipeline H1 2023 growth Strategic business development throu
Slide 31: AstraZeneca at COP27
AstraZeneca at COP27 Driving landmark, sector-wide action SMI Health Systems Taskforce Commitments Supply chains – supplier standards & renewable PPA Patient care pathways – raising awareness & better transparency Digital healthcare – goal to decarbonise clinical trials AZN Ambition Zero Carbon Scop
Slide 32: YTD 2022 Question & Answer Session
Pascal Soriot Aradhana Sarin Executive Director and Chief Executive Director and Chief Executive Officer Financial Officer Dave Fredrickson Susan Galbraith Executive Vice President, Executive Vice President, YTD 2022 Oncology Business Oncology R&D Question & Ruud Dobber Mene Pangalos Executive Vice
Slide 33: Appendix
Appendix • Oncology Breast Cancer schematic • Emerging Markets • ESG & corporate sustainability • Late-stage pipeline catalysts • Key performance by geography, disease area
Slide 34: Oncology: positioned to address the full spectrum of breast cancer
APPENDIX | Breast cancer landscape Oncology: positioned to address the full spectrum of breast cancer Redefining the classification of breast cancer through monotherapy and combinations Early 1st-line 2nd-line 3rd-line 3rd-line+ HER2-high HER2-high HER2-high Enhertu + potential combos Enhertu + pote
Slide 35: Emerging Markets: YTD 2022
APPENDIX | Emerging Markets Emerging Markets: YTD 2022 Total Revenue $9bn, +8% including Vaxzevria1 Emerging Markets, 8% China, -1%; ex-China EM, +20% 4,000 EM Total Revenue YTD highlights: 3,500 Q3 2022 | % EM Total Revenues • Oncology: Tagrisso +22%, Lynparza +30% 3,000 • CVRM: Farxiga +46% 2,500
Slide 36: Q3 2022 ESG performance highlights
APPENDIX | ESG & corporate sustainability Q3 2022 ESG performance highlights Access to healthcare Environmental protection Ethics and transparency 29m+ 1 of 7 350 young women Hypertension screenings through Member companies of the Sustainable Across 35 countries stepped into Healthy Heart Africa sin
Slide 37: Oncology: Tagrisso and Imfinzi
APPENDIX | YTD 2022 Product Performance Oncology Tagrisso Imfinzi 16% growth to $4,102m 19% growth to $2,031m 1,600 800 1,400 700 1,200 600 Total Revenue ($m) Total Revenue ($m) 1,000 500 800 400 600 300 400 200 200 100 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2022 2021 2022 EM 306 390 315
Slide 38: Oncology: Lynparza
APPENDIX | YTD 2022 Product Performance Oncology Lynparza Lynparza 19% growth to $1,949m (excludes Collaboration Revenue) Collaboration Revenue: $3.7bn recorded, $4.0bn future potential 800 1000 700 600 800 Update with Cumulative milestones received and remaining Total Revenue ($m) 500 Collaboration
Slide 39: Oncology: Calquence and Enhertu
APPENDIX | YTD 2022 Product Performance Oncology Calquence Enhertu 77% growth to $1,469m >2x growth to $387m 600 200 180 500 160 140 Total Revenue ($m) Total Revenue ($m) 400 120 300 100 80 200 60 40 100 20 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2022 2021 2022 EM 2 5 5 8 7 8 12 EM 1 3 4
Slide 40: BioPharmaceuticals: Cardiovascular, Renal and Metabolism
APPENDIX | YTD 2022 Product Performance BioPharmaceuticals: Cardiovascular, Renal and Metabolism Farxiga Brilinta Lokelma 58% growth to $3,208m 7% decrease to $1,013m 80% growth to $208m 1,200 400 90 350 80 1,000 70 300 800 60 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 250 50 600 200 4
Slide 41: BioPharmaceuticals: Respiratory & Immunology
APPENDIX | YTD 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Symbicort Fasenra 2% decrease to $1,919m 17% growth to $1,015m 800 400 700 350 600 300 Total Revenue ($m) Total Revenue ($m) 500 250 400 200 300 150 200 100 100 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021
Slide 42: BioPharmaceuticals: Respiratory & Immunology
; APPENDIX | YTD 2022 Product Performance BioPharmaceuticals: Respiratory & Immunology Breztri Pulmicort >2x growth to $282m 31% decline to $479m 120 350 100 300 250 Total Revenue ($m) Total Revenue ($m) 80 200 60 150 40 100 20 50 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2021 2022 2021 2022 EM
Slide 43: Rare Disease
APPENDIX | YTD 2022 Product Performance Rare Disease Soliris Ultomiris Strensiq 2% decrease to $2,918m 35% growth to $1,371m 15% growth to $687m 1,200 600 300 1,000 500 250 800 400 200 Total Revenue ($m) Total Revenue ($m) Total Revenue ($m) 600 300 150 400 200 100 200 100 50 0 0 0 Q1 Q2 Q3 Q4 Q1 Q2
Slide 44: Use of AstraZeneca slides from conference calls and webcasts
Use of AstraZeneca slides from conference calls and webcasts The AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to th